Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dinaciclib + PLX51107 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dinaciclib | SCH727965|MK-7965|SCH-727965 | CDK1 Inhibitor 13 CDK2 Inhibitor 31 CDK5 Inhibitor 8 CDK9 Inhibitor 21 | Dinaciclib (SCH 727965) inhibits cyclin dependent kinases CDK1, CDK2, CDK5, CDK9, and CDK12, which prevents phosphorylation of downstream targets and may promote cell cycle arrest and apoptosis in cancer cells (PMID: 24900195, PMID: 24004674, PMID: 27880910, PMID: 32269732). | |
PLX51107 | PLX-51107|PLX 51107 | BET Inhibitor (Pan) 32 | PLX51107 is a small molecule BET inhibitor, which binds to BET bromodomains in BRD2, BRD3, BRD4, and BRDT, potentially resulting in decreased tumor cell proliferation (PMID: 29386193, PMID: 31063649, PMID: 32717030). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|